Literature DB >> 6418046

Flurazepam attenuates the arousal response to CO2 during sleep in normal subjects.

L L Hedemark, R S Kronenberg.   

Abstract

Increased episodes and duration of apnea during sleep associated with arterial oxygen desaturation have been reported after administration of flurazepam. We postulated that an alteration in respiratory control during sleep might be the underlying mechanism of this observation. Accordingly, we measured isocapnic hypoxic and hyperoxic hypercapnic ventilatory and arousal responses during natural (NS) and during flurazepam-induced (FS) sleep. We found no significant difference in the ventilatory response to hypoxia during FS compared with that during NS in 8 normal subjects. Similarly, although the ventilatory response to hypercapnia was performed in only 4 of the 8 subjects during FS, no significant difference from that during NS was noted in these subjects. There was, however, a significant decrease in the number of hypercapnic response tests in which arousal occurred after flurazepam administration (85% in NS versus 54% in FS; p less than 0.005). Additionally, an increase was seen in the mean PACO2 level at which arousal occurred during FS (51 +/- 1.6, means +/- SEM) as compared with that during NS (49 +/- 0.9; p less than 0.07). A similar but not significant decrease was noted in the number of hypoxic response tests in which arousal occurred (28% during NS versus 17% during FS). We conclude that while ventilatory responses to hypoxia and hypercapnia are normal during sleep after flurazepam administration, a decrease in arousal response is seen after administration of this drug in normal subjects. This alteration in arousal response may be the pathogenic mechanism of the increased duration of apnea reported in association with flurazepam.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418046     DOI: 10.1164/arrd.1983.128.6.980

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

Review 1.  Comorbid insomnia in sleep-related breathing disorders: an under-recognized association.

Authors:  Suhaila E Al-Jawder; Ahmed S Bahammam
Journal:  Sleep Breath       Date:  2011-03-29       Impact factor: 2.816

2.  [Sleep, respiration and benzodiazepines: effects of benzodiazepines on nocturnal respiration].

Authors:  P Lemoine
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

3.  Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold.

Authors:  Danny J Eckert; Robert L Owens; Geoffrey B Kehlmann; Andrew Wellman; Shilpa Rahangdale; Susie Yim-Yeh; David P White; Atul Malhotra
Journal:  Clin Sci (Lond)       Date:  2011-06       Impact factor: 6.124

4.  Patients with treatment-resistant insomnia taking nightly prescription medications for sleep: a retrospective assessment of diagnostic and treatment variables.

Authors:  Barry Krakow; Victor A Ulibarri; Edward A Romero
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold.

Authors:  Erik T Smales; Bradley A Edwards; Pam N Deyoung; David G McSharry; Andrew Wellman; Adrian Velasquez; Robert Owens; Jeremy E Orr; Atul Malhotra
Journal:  Ann Am Thorac Soc       Date:  2015-05

6.  Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease.

Authors:  M A Cohn; D D Morris; D Juan
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

7.  Concomitant benzodiazepine and opioids decrease sleep apnoea risk in chronic pain patients.

Authors:  Soodaba Mir; Jean Wong; Clodagh M Ryan; Geoff Bellingham; Mandeep Singh; Rida Waseem; Danny J Eckert; Frances Chung
Journal:  ERJ Open Res       Date:  2020-08-25

8.  Improvement of idiopathic central sleep apnea with zolpidem.

Authors:  Syed Quadri; Christopher Drake; David W Hudgel
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.